NightstaRx工商信息_电话_地址_信用信息_财务信息

公司简介

We are a clinical-stage company focused on developing and commercializing a pipeline of novel and potentially curative, one-time retinal gene therapies for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness, and, for which, there are no currently approved treatments.

主要成员

David Fellows、Chris Hollowood David Lubner、Professor Robert MacLaren、James McArthur、David Mott

产品/服务

Choroideremia (CHM)

CHM is a rare, degenerative, X-linked genetic retinal disorder primarily affecting males.

One-time retinal gene therapy

For patients with rare hereditary retinal diseases.

NSR-REP1	choroideremia (CHM).
NSR-RPGR	X-linked retinitis pigmentosa (XLRP)
NSR-BEST1	Yolk-like macular dystrophy

融资信息

融资轮次	融资日期	投资方	融资额度
A轮	2014-01	未披露	未披露
创业	2014-02	未披露	GBP12M
B轮	2015-11	New Enterprise Associates	$35M

关联公司